Risovalisib Yields Highest Reported Monotherapy Response Rate in Ovarian Clear Cell Carcinoma
In an ongoing, single-arm, multicenter phase II trial involving patients with recurrent or persistent PIK3CA-mutated ovarian clear cell carcinoma, treatment with the PI3Kα inhibitor risovalisib yielded the highest objective response rate reported to date with monotherapy for this cancer, according to Li et al. The findings, published in The Lancet Oncology, also demonstrated a manageable safety profile.
“The antitumor activity of risovalisib monotherapy showed in this trial supports risovalisib as an effective targeted treatment option,” the investigators wrote.
Study Details
A total of 93 female patients (median age = 49 years) with recurrent or persistent PIK3CA-mutated ovarian clear cell carcinoma who had received one to three prior lines of systemic therapy (≥ 2 lines: 68%) were enrolled and treated across 27 centers in China (44% of patients) and 12 centers in Japan (56% of patients). They received 40 mg of oral risovalisib daily in 21-day cycles until disease progression, unacceptable toxicity, or other protocol-defined reasons for discontinuation.
The primary endpoint was blinded independent review committee–assessed objective response rate among all treated patients with confirmed PIK3CA hotspot mutations and measurable disease at baseline. Safety was evaluated in all patients who received at least one dose.
Follow-up data were provided for a median of 14.5 months.
Key Findings
Of the 84 patients in the efficacy analysis set, 29 (35%) experienced an objective response.
Rash (32%), hyperglycemia (30%), and decreased weight (8%) were the most frequently reported treatment-related adverse events of grade 3 or higher in the safety analysis set. A total of 39% of patients experienced a treatment-related serious adverse event; the most common were rash (9%), pneumonitis (6%), and decreased appetite (4%). No treatment-related deaths were documented.
“These results support risovalisib as a potential novel treatment option for PIK3CA-mutated ovarian clear cell carcinoma, a rare yet lethal cancer in dire need of additional treatment options,” the investigators concluded. “Combination strategies including risovalisib could also be explored to further increase efficacy observed in this study.”
Jihong Liu, PhD, of Sun Yat-sen University Cancer Center, Guangzhou, China, and Xiaohua Wu, MD, PhD, of Fudan University Shanghai Cancer Center, China, are the corresponding authors of the article in The Lancet Oncology.
Disclosure: The study was funded by Haihe Biopharma. For full disclosures of the study authors, visit thelancet.com.